Possible mechanisms of action of azithromycin in cystic fibrosis

C. Cigana, E. Nicolis, B. M. Assael, P. Melotti (Verona, Italy)

Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle
Session: Cystic fibrosis lung disease: pieces of the puzzle
Session type: Oral Presentation
Number: 1629

Congress or journal article abstractSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Cigana, E. Nicolis, B. M. Assael, P. Melotti (Verona, Italy). Possible mechanisms of action of azithromycin in cystic fibrosis. Eur Respir J 2005; 26: Suppl. 49, 1629

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Emerging pathogens in cystic fibrosis
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=66
Year: 2006

Pharmacological treatment of the biochemical defect in cystic fibrosis airways
Source: Eur Respir J 2001; 17: 1314-1321
Year: 2001



An anti-inflammatory effect of azithromycin in cystic fibrosis
Source: Annual Congress 2010 - New aspects of cystic fibrosis
Year: 2010

Gene therapy for cystic fibrosis: successes and challenges
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=79
Year: 2006

New insights into the pathophysiology of lung disease in cystic fibrosis patients
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=1
Year: 2006

Once-daily tobramycin in the treatment of adult patients with cystic fibrosis
Source: Eur Respir J 2002; 19: 303-309
Year: 2002



Managing antimicrobial resistance in cystic fibrosis
Source: International Congress 2014 – ERS/Lancet and Lancet Respiratory Medicine joint session: complicating infections in respiratory disease and critical care
Year: 2014



The oral AntibioticS approprIateness score (OASIS) – A novel scoring system to assess antibiotic route in pulmonary exacerbations of cystic fibrosis (CF)
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013


The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects
Source: Eur Respir Rev, 30 (161) 210055; 10.1183/16000617.0055-2021
Year: 2021



Atypical cystic fibrosis
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=38
Year: 2006

Daily versus weekly azithromycin in cystic fibrosis patients
Source: Eur Respir J 2007; 30: 487-495
Year: 2007



Cystic fibrosis: prospects for therapy of some class 1 mutations
Source: Annual Congress 2007 - Cystic fibrosis: will the new biology deliver?
Year: 2007


The characteristics of the minimum inhibitory concentration of antibiotics on pulmonary infections in patients with cystic fibrosis
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015


Lack of therapeutic potential for topical metformin in treatment of airway secretion dehydration in cystic fibrosis
Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease
Year: 2009


Hypoxia and sterile inflammation in cystic fibrosis airways: mechanisms and potential therapies
Source: Eur Respir J 2017; 49(1): 1600903; DOI: 10.1183/13993003.00903-2016
Year: 2017



The pharmacokinetic of the main oral antibiotics in children with cystic fibrosis.
Source: International Congress 2019 – Treatments, adherence and psychosocial aspects of cystic fibrosis
Year: 2019


Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients
Source: Eur Respir J 2002; 20: Suppl. 38, 342s
Year: 2002

Cystic fibrosis
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-50-2, page=234
Year: 2006

Cystic fibrosis
Source: Respipedia Article
Year: 2018

Antibiotic treatment of cystic fibrosis lung disease
Source: Eur Respir Monogr 2014; 64: 188-202
Year: 2014